OR51D1 Antibody

What is OR51D1 and what is its biological significance?

OR51D1 is a member of the olfactory receptor family, specifically belonging to the G-protein coupled receptor 1 family. Olfactory receptors interact with odorant molecules in the nose to initiate neuronal responses that trigger smell perception. These receptors share a 7-transmembrane domain structure with many neurotransmitter and hormone receptors and are responsible for recognition and G protein-mediated transduction of odorant signals . The olfactory receptor gene family is actually the largest gene family in the human genome. While typically expressed in olfactory neurons, certain olfactory receptors (termed "ectopic ORs") have been found in non-olfactory tissues, suggesting additional physiological roles beyond smell perception.

What applications are OR51D1 antibodies typically used for in research?

OR51D1 antibodies are utilized in multiple experimental techniques, primarily:

• Western Blotting (WB): For detecting OR51D1 protein in cell or tissue lysates, typically at the expected molecular weight of approximately 34 kDa

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative measurement of OR51D1 in samples

• Immunofluorescence (IF): For visualizing the cellular localization of OR51D1

• Immunocytochemistry (ICC): For detecting OR51D1 in cultured cells

The application dilutions typically recommended for these methods are:

• WB: 1:500-1:2000 or 1:500-1:1000

• IF/ICC: 1:100-1:500

• ELISA: 1:20000-1:40000 for peptide ELISA

How do I determine the appropriate antibody concentration for my experiments?

The optimal antibody concentration depends on several factors including the abundance of the target protein, the specific application, and the sensitivity of your detection system. Begin with the manufacturer's recommended dilutions (see 1.2 above) and perform a titration experiment.

For Western blotting, test a range of antibody dilutions (e.g., 1:500, 1:1000, 1:2000) using a positive control sample known to express OR51D1. Select the concentration that provides the strongest specific signal with minimal background. Remember that OR51D1 is a membrane protein, so appropriate sample preparation is crucial for successful detection. The expected band should appear at approximately 34 kDa, though as a glycosylated GPCR, it may show a somewhat fuzzy appearance on SDS-PAGE gels . Additionally, some researchers report detecting GPCR dimers at approximately 70 kDa .

What controls should I include when using OR51D1 antibodies?

To ensure experimental validity, include these controls:

• Positive control: Samples known to express OR51D1 (e.g., certain olfactory tissue samples or transfected cells overexpressing OR51D1)

• Negative control: Samples known not to express OR51D1

• Primary antibody omission control: Include a sample treated identically but without the primary antibody to assess secondary antibody specificity

• Peptide competition control: Pre-incubate the antibody with the immunizing peptide before application to validate specificity

• Loading control: For Western blots, include detection of a housekeeping protein to ensure equal loading across samples

These controls help distinguish specific signals from background or non-specific binding.

How can I validate OR51D1 antibody specificity in my experimental system?

• Overexpression system: Generate cells overexpressing FLAG-tagged OR51D1 and compare detection between anti-OR51D1 and anti-FLAG antibodies. Research suggests that commercial anti-GPCR antibodies sometimes fail to detect their targets even when overexpressed, so this validation is crucial .

• Knockdown/knockout validation: Compare antibody signal in wild-type samples versus those where OR51D1 has been knocked down using siRNA or knocked out using CRISPR-Cas9.

• Mass spectrometry validation: Immunoprecipitate with the OR51D1 antibody and identify the pulled-down proteins using mass spectrometry to confirm target identity.

• Deglycosylation test: As OR51D1 is a glycosylated protein, treatment with deglycosylation enzymes should cause a molecular weight shift and band sharpening on Western blots, as observed with other olfactory receptors (shifting from ~40 kDa to ~32 kDa) .

• Functional validation: Correlate antibody detection with functional assays for GPCR activity, such as cAMP production upon ligand stimulation.

What are the key methodological considerations for detecting ectopically expressed OR51D1 in non-olfactory tissues?

When investigating OR51D1 expression outside traditional olfactory tissues, consider these methodological approaches:

• Sensitivity optimization: As ectopic expression may be lower than in olfactory tissues, optimize detection sensitivity by:

  • Using signal amplification methods like TSA (tyramide signal amplification) for immunohistochemistry

  • Employing more sensitive detection reagents for Western blotting

  • Considering RT-qPCR to validate protein detection with transcript presence

• Cross-reactivity elimination: Ensure specificity by:

  • Testing antibodies on tissues from knockout models if available

  • Using multiple antibodies targeting different epitopes of OR51D1

  • Performing peptide competition assays to confirm specificity

• Context-appropriate controls: Include tissue-specific controls relevant to your research question. For example, when studying potential OR51D1 expression in prostate cancer, use both normal prostate tissue and established prostate cancer cell lines with known OR expression profiles as reference points .

• Subcellular localization analysis: Confirm proper trafficking of OR51D1 to the plasma membrane using cell surface biotinylation or membrane fractionation techniques in combination with immunofluorescence microscopy .

How does OR51D1 function compare to other olfactory receptors that have been implicated in cancer biology?

While direct research on OR51D1 in cancer is limited in the provided search results, related olfactory receptors OR51E1 and OR51E2 provide insights into potential functional mechanisms:

• Proliferation effects: OR51E1 and OR51E2 overexpression has been shown to suppress proliferation of LNCaP prostate cancer cells, suggesting a cytostatic effect. This effect appears to be specific to these particular ORs, as overexpression of another olfactory receptor (OR2AT4) did not produce the same effect .

• Cell death induction: OR51E1 overexpression promotes markers of cell death, including annexin V staining, suggesting these receptors may induce apoptosis in cancer cells .

• Signaling pathway engagement: OR51E1 activation increases ERK1/2 phosphorylation and upregulates cytostatic and cell death markers including p27, p21, and p53 .

• Cell type specificity: The anti-proliferative effects appear to be cell-type specific. For example, OR51E1 overexpression inhibited LNCaP cell proliferation but had no effect on HEK293 cells .

• Ligand specificity: Olfactory receptors respond to specific ligands. For OR51E1, certain aliphatic acids (like butyrate) serve as agonists and enhance the cytostatic effect .

When studying OR51D1, researchers should investigate whether it shares these cancer-relevant properties by:

• Testing its expression in various cancer cell lines

• Assessing its effects on cell proliferation and apoptosis when overexpressed

• Identifying potential ligands that activate the receptor

• Examining downstream signaling pathway activation

What is the recommended protocol for using OR51D1 antibodies in Western blotting?

Protocol for Western Blotting with OR51D1 Antibody:

• Sample preparation:

  • For cell lysates: Harvest cells and lyse in RIPA buffer containing protease inhibitors

  • For membrane proteins like OR51D1, include 1% SDS or other strong detergents to ensure solubilization

  • Do not boil samples to avoid aggregation of transmembrane proteins

• Gel electrophoresis:

  • Load 20-50 μg of total protein per lane

  • Use 10-12% SDS-PAGE gels for optimal resolution around the 34 kDa range

• Transfer and blocking:

  • Transfer to PVDF membrane (preferred for hydrophobic proteins)

  • Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Primary antibody incubation:

  • Dilute OR51D1 antibody 1:500-1:2000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

• Secondary antibody:

  • Wash membrane 3x with TBST

  • Incubate with appropriate HRP-conjugated secondary antibody (anti-rabbit for polyclonal or anti-mouse for monoclonal ) at 1:5000 dilution for 1 hour at room temperature

• Detection:

  • Wash membrane 3x with TBST

  • Apply ECL substrate and detect signal using imaging system

  • Expected molecular weight: approximately 34 kDa

  • Note that as a glycosylated GPCR, OR51D1 may appear as a somewhat fuzzy band, and deglycosylation treatment can cause a shift to lower molecular weight

How can I optimize immunofluorescence staining for OR51D1 in cultured cells?

Optimized Immunofluorescence Protocol for OR51D1:

• Cell preparation:

  • Culture cells on glass coverslips or chamber slides

  • For improved adhesion of suspension cells, pre-coat surfaces with poly-L-lysine

• Fixation options:

  • For membrane protein preservation: 4% paraformaldehyde (PFA) for 15 minutes at room temperature

  • Alternative: methanol fixation for 10 minutes at -20°C (may better expose some epitopes)

• Permeabilization:

  • For PFA-fixed cells: 0.1-0.2% Triton X-100 in PBS for 10 minutes

  • For methanol-fixed cells: additional permeabilization is typically unnecessary

• Blocking:

  • Block with 5% normal serum (from the species of secondary antibody) with 1% BSA in PBS for 30-60 minutes

• Primary antibody:

  • Dilute OR51D1 antibody 1:100-1:500 in blocking solution

  • Incubate overnight at 4°C in a humidified chamber

• Secondary antibody:

  • Wash 3x with PBS

  • Incubate with fluorophore-conjugated secondary antibody at 1:500-1:1000 dilution for 1 hour at room temperature in the dark

  • Include nuclear counterstain (e.g., DAPI) during the final 10 minutes

• Mounting and imaging:

  • Mount coverslips using anti-fade mounting medium

  • Image using confocal or fluorescence microscopy

  • Look for membrane localization pattern as expected for a GPCR

For transfected cells expressing recombinant OR51D1, consider using epitope tags (e.g., FLAG) for detection, as this approach has proven effective for visualizing olfactory receptors on the cell surface .

What methods are recommended for investigating OR51D1 function in cellular models?

To study OR51D1 function, consider these methodological approaches:

• Inducible expression system:

  • Utilize tetracycline-inducible expression systems to control OR51D1 expression levels

  • This approach has been successful for studying other olfactory receptors that might have cytostatic effects

  • Add rhodopsin or other tag sequences that facilitate GPCR expression and trafficking

• cAMP signaling assays:

  • As a GPCR, OR51D1 likely signals through G-proteins that affect cAMP levels

  • Use real-time cAMP biosensors or PKA phosphorylation detection to measure receptor activation

  • Protocol for PKA activity: Use antibodies against the phosphorylated peptide corresponding to the phosphorylation consensus motif (RxxS*/T*) of PKA substrates

• Calcium imaging:

  • For Gq-coupled activity, measure intracellular calcium changes using calcium-sensitive dyes or genetically encoded calcium indicators

• Ligand screening:

  • Test potential ligands using the functional assays above

  • Apply systematic structural variations to identify structure-activity relationships

  • Consider testing aliphatic acids and structurally similar compounds, which have activated other olfactory receptors

• Cell proliferation and viability assays:

  • Monitor cell confluence over time following OR51D1 overexpression or activation

  • Use MTT/XTT assays or real-time cell analysis systems for quantitative measurements

  • Assess markers of cell cycle arrest (p21, p27) and apoptosis (annexin V staining)

How do I troubleshoot weak or absent signals in Western blots with OR51D1 antibody?

If you're experiencing weak or no signal when using OR51D1 antibody in Western blotting, consider these potential issues and solutions:

Note that commercial antibodies against GPCRs sometimes fail to detect even overexpressed receptors , so validation with tagged constructs is recommended.

What factors affect OR51D1 antibody sensitivity and specificity in immunostaining applications?

Several factors can influence the performance of OR51D1 antibodies in immunostaining:

• Fixation method impact:

  • Over-fixation with aldehydes can mask epitopes

  • Alternative fixatives (methanol, acetone) may better preserve certain epitopes

  • Test multiple fixation protocols to determine optimal conditions

• Epitope accessibility:

  • The antibody targets the N-terminal region (AA 33-82) of OR51D1

  • This region may be differently accessible depending on protein conformation

  • Enhanced permeabilization may be necessary for accessing intracellular epitopes

• Antigen retrieval considerations:

  • Heat-induced epitope retrieval (HIER) may improve detection in over-fixed samples

  • For paraffin sections, try citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Enzymatic retrieval with proteinase K can be an alternative for membrane proteins

• Signal amplification options:

  • Tyramide signal amplification (TSA) can enhance sensitivity by 10-100 fold

  • Biotin-streptavidin systems offer amplification but may increase background

  • Polymer detection systems can improve signal-to-noise ratio

• Background reduction strategies:

  • Include 0.1-0.3% Triton X-100 in antibody diluent to reduce non-specific binding

  • Pre-adsorb secondary antibodies with tissue powder from the species being examined

  • Include additional blocking agents (e.g., fish gelatin, casein) for problematic samples

How might OR51D1 expression and function relate to disease states based on research with other olfactory receptors?

Based on research with related olfactory receptors, particularly OR51E1 and OR51E2, several potential disease-relevant functions of OR51D1 warrant investigation:

• Cancer biology implications:

  • Certain olfactory receptors (OR51E1, OR51E2) are upregulated in prostate cancer

  • Overexpression of these receptors suppresses cancer cell proliferation and induces cell death markers

  • OR51D1 may exhibit similar tumor-suppressive properties in specific cancer types

  • Researchers should examine OR51D1 expression across cancer types and correlate with clinical outcomes

• Signaling pathway interactions:

  • OR51E1 activates ERK1/2 phosphorylation and upregulates p27, p21, and p53

  • OR51D1 may engage similar or distinct signaling pathways

  • Investigate potential crosstalk between OR51D1 and established cancer signaling networks

• Tissue-specific functions:

  • Effects of olfactory receptors can be cell-type specific (e.g., OR51E1 affects LNCaP but not HEK293 cells)

  • Determine tissue distribution of OR51D1 beyond olfactory epithelium

  • Explore potential physiological roles in tissues with confirmed expression

• Ligand-dependent activation:

  • Identify endogenous OR51D1 ligands in various tissues

  • Explore whether endogenous metabolites or microbial products can activate OR51D1

  • Develop synthetic ligands for targeted activation in therapeutic contexts

What are the latest methodological advances for studying OR51D1 and other GPCRs in complex biological systems?

Recent methodological advances applicable to OR51D1 research include:

• CRISPR-based approaches:

  • CRISPR-Cas9 knockout models to study loss-of-function phenotypes

  • CRISPR activation (CRISPRa) for endogenous gene upregulation

  • Knock-in of epitope tags for improved detection of endogenous protein

• Single-cell analysis techniques:

  • Single-cell RNA-seq to identify cell populations expressing OR51D1

  • CyTOF mass cytometry for protein-level detection across heterogeneous tissues

  • Spatial transcriptomics to map OR51D1 expression in tissue context

• Advanced imaging methods:

  • Super-resolution microscopy (STORM, PALM) for nanoscale localization

  • FRET/BRET sensors to study receptor-effector interactions in living cells

  • Light-sheet microscopy for 3D visualization in tissue samples

• Functional genomics screening:

  • CRISPR screens to identify genes affecting OR51D1 expression or function

  • Synthetic lethality screens to find context-dependent functions

  • Drug-gene interaction screens to discover pathway modulators

• Real-time signaling biosensors:

  • Novel fluorescence-based real-time cAMP biosensors

  • GPCR conformation sensors to detect active versus inactive states

  • Multiplexed biosensors for simultaneous monitoring of multiple pathways

How can I integrate multiple antibody-based approaches to build a comprehensive understanding of OR51D1 biology?

Developing a complete picture of OR51D1 biology requires integrating multiple complementary approaches:

• Multi-level expression analysis:

  • Combine transcriptomic data (RNA-seq, qPCR) with protein detection (Western blot, immunostaining)

  • Correlate expression levels with functional readouts in the same systems

  • Use inducible expression systems to create controlled expression gradients

• Structure-function correlation:

  • Map epitopes recognized by different antibodies to specific protein domains

  • Correlate structural features with functional consequences using mutagenesis

  • Use antibodies targeting different domains to probe conformation changes upon activation

• Temporal dynamics investigation:

  • Study acute versus chronic effects of receptor activation

  • Track receptor internalization and recycling following ligand exposure

  • Monitor downstream signaling activation kinetics in real-time

• Pathway validation approaches:

  • Confirm antibody-detected phenomena with orthogonal methods

  • Validate functional effects with both gain- and loss-of-function approaches

  • Use pathway inhibitors to establish causality in observed phenotypes